| High LDL-C population (LDL-C ≥5.0 mmol/l),n = 236, n % | Hypercholesterolaemia without potential secondary cause (subgroup),n = 115, n % | |
|---|---|---|
| Patients with CVD diagnoses | ||
| Treatment target — LDL-C > 1.8 mmol/ l | ||
| Total number of patients | 68 (28.8) | 34 (29.6) |
| Patients receiving statins | 51 (75.0) | 26 (76.5) |
| Other lipid-lowering therapy | 2 (2.9) | 0 (0.0) |
| Maximum dosage of statins | 28 (54.9) | 15 (57.7) |
| Patients reaching treatment targeta | 3 (4.4) | 2 (5.9) |
| LDL-C mean mmol/l (IQR) | ||
| Maximum registered | 5.16 (4.90–5.60) | 4.94 (5.00–5.40) |
| Adjusted pre-treatment | 6.36 (5.36–6.73) | 6.51 (5.30–7.18) |
| Latest follow-up | 3.31 (2.50–4.10) | 3.44 (2.60–4.20) |
| Patients without CVD diagnoses | ||
| Treatment target – LDL-C > 2.6 mmol/ l | ||
| Total number of patients | 168 (71.2) | 81 (70.4) |
| Patients receiving statins | 67 (39.9) | 22 (27.2) |
| Other lipid-lowering therapy | 2 (1.2) | 0 (0.0) |
| Maximum dosage of statins | ||
| Overall | 36 (53.7) | 15 (68.2) |
| Possible FH | 28 (77.8) | 10 (66.7) |
| Probable FH | 3 (8.3) | 1 (6.7) |
| Definite FH | 5 (13.9) | 4 (26.7) |
| Patients reaching treatment target | ||
| Overall | 22 (13.1) | 6 (7.4) |
| Possible FH | 22 (100) | 6 (100) |
| Probable FH | 0 (0.0) | 0 (0.0) |
| Definite FH | 0 (0.0) | 0 (0.0) |
Subgroup has been derived from the high LDL-C population. aTreatment target as defined in the 2016 European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) guidelines for management of dyslipidaemia.16 CVD = cardiovascular disease. FH = familial hypercholesteroleamia. LDL-C = low-density lipoprotein cholesterol.